Why GLP-1s aren't lowering employers' costs

Employer coverage of GLP-1 weight loss medications like Ozempic and Zepbound is rising, yet the financial logic behind these benefits remains contentious. While one in eight U.S. adults now uses these drugs, only 20% of employer health plans provide coverage, often under the assumption that improved employee health will reduce long-term medical claims. However, health economist Chris Whaley characterizes this as "magical thinking," noting that high drug costs, expensive management programs, and the fact that long-term health benefits often accrue to Medicare rather than the employer prevent immediate savings. Current cost reductions for employers stem primarily from strict access controls rather than improved patient health outcomes. Despite these economic realities, the drugs provide significant personal benefits, including reduced "food noise" and improved quality of life, suggesting that the value of these medications may extend beyond simple balance-sheet calculations.